In our cohort, we found an upregulation of Tim-3 at resistance in the tumor specimen of patient #6 (Supplementary Fig. 9), while TIGIT upregulation was found at resistance in patients #3 and #7, suggesting that in these patients, new resistance mechanisms involving these immune checkpoints, occur. This evidence concerns the gene HAVCR2 and neoplasm.